金吾财讯 | 据港交所5月31日披露，泰德医药（浙江）向港交所主板提交上市申请，摩根士丹利、中信证券为联席保荐人。
根据弗若斯特沙利文的资料，就2023年销售收入而言，公司是全球第三大专注于多肽的合约研究、开发及生产机构（CRDMO）。
财务方面，公司于2021-2023年分别录得收益2.82亿、3.51亿及3.37亿元人民币，同期对应年内利润8027.8万、5398万及4890.5万元人民币。
English
Back
- Markets
- Features
- News
- Community
- Learn
- Help Center
- About
- Offers & Rewards
- Welcome RewardsOpen an account and get up to HKD2000!
- Enjoy limited-time 5%+5% returns on Cash PlusInvest any amount and enjoy a 5% average return on Cash Plus + 5% welcome reward
- Join Futubull Membership ProgramUnlock 11 Premier Benefits
- Referral PromotionBring a friend and collect up to HK$600 in rewards
- Learn PremiumAnalyst 1V1 online teaching
- Stock TransferSwitch to Futu and get up to HK$7,000 in rewards
- English
- 繁體中文
- 简体中文
- Dark
- Light
- Headlines
- 【新股IPO】泰德医药向港交所主板提交上市申请
【新股IPO】泰德医药向港交所主板提交上市申请
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Hot News
Updated
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.